Polymorphisms in the 5α-Reductase Type 2 Gene and Response to Finasteride Treatment in BPH

The study investigated the relationship between polymorphisms in the 5α-reductase type 2 gene and the response to finasteride treatment in patients with benign prostatic hyperplasia (BPH). The research aimed to determine if genetic variations could predict the effectiveness of finasteride, a common treatment for BPH. The findings suggested that certain polymorphisms in the gene might influence the therapeutic outcomes of finasteride, potentially guiding personalized treatment strategies for BPH patients. However, the document did not specify the number of participants involved in the study, which is crucial for assessing the strength of the findings.